Back from the dead: Nek­tar hunts a block­buster deal as opi­oid '181 looks less ad­dic­tive than oxy

Af­ter whip­ping up some up­beat an­a­lyst as­sess­ments in March with a pos­i­tive late-stage ef­fi­ca­cy study for their mu-opi­oid pain ther­a­py NK­TR-181, Nek­tar Ther­a­peu­tics has now …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER